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The unfolded protein response (UPR) can coordinate the regulation of gene transcription and protein translation to balance
the load of client proteins with the protein folding and degradative capacities of the ER. Increasing evidence also implicates the
UPR in the regulation of lipid synthesis and membrane biogenesis. The diﬀerentiation of B lymphocytes into antibody-secreting
cells is marked by signiﬁcant expansion of the ER, the site for antibody synthesis and assembly. In activated B cells, the demand for
membraneproteinandlipidcomponentsleadstoactivationoftheUPRtranscriptionalactivatorXBP1(S)which,inturn,initiatesa
cascadeofbiochemicaleventsthatenhancesuppliesofphospholipidprecursorsandbuildmachineryforthesynthesis,maturation,
and transport of secretory proteins. The alterations in lipid metabolism that occur during this developmental transition and the
impact of membrane phospholipid restriction on B cell secretory characteristics are discussed in this paper.
1.Introduction
Activated B lymphocytes proliferate and proceed along
distinct developmental pathways that determine their func-
tion and fate. Speciﬁcally, responding B cells can rapidly
diﬀerentiate in extrafollicular sites into short-lived antibody-
secretingcellsthatpredominantlysecreteIgMantibodies[1].
Alternatively, responding B cells can enter germinal centers,
undergo somatic hypermutation and isotype switching,
and then become memory B cells or long-lived antibody-
secreting cells [2]. Extrinsic factors, including the nature of
the antigen and T cell help in the form of membrane-bound
molecules and soluble cytokines, play key roles in regulating
B cell responses. However, intrinsic signals are also pivotal
in directing the fate of responding B cells as evidenced by
the critical role of the unfolded protein response (UPR)
transcription factor XBP1(S) in driving the diﬀerentiation
of antibody-secreting cells [3, 4], the eﬀectors of humoral
immunity. Here, we discuss the current understanding of
the relationship between the UPR, lipid biosynthesis and
organelle biogenesis in activated B cells.
2. LipidSupplyand Demand
B lymphocytes proliferate and diﬀerentiate into antibody-
secreting cells upon interaction with speciﬁc antigen or
certain Toll-like receptor (TLR) ligands. When B cells are
stimulated to enter the cell cycle and proliferate, the mech-
anisms that control the membrane phospholipid supply in
rapidly dividing cells are engaged. The division of one cell
into two daughter cells requires a doubling of membrane
content during cell cycle progression [5]. Phosphatidyl-
choline (PtdCho) is the major membrane phospholipid in
mammalian cells and is a precursor to the two other most
abundant membrane phospholipids, sphingomyelin (SM)
[6]andphosphatidylethanolamine(PtdEtn)[7].PtdChoand
the other phospholipids accumulate in a periodic manner
during S phase, coincident with DNA synthesis. The net
increase in membrane PtdCho results from an interaction
between cell cycle-dependent oscillations in the rates of
PtdCho biosynthesis and degradation. PtdCho synthesis
is stimulated very early during G1 phase [8–10], but is
accompaniedbyrapidPtdChoturnover.Twophospholipases
have been implicated in the PtdCho turnover associated with2 Biochemistry Research International
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Figure 1: Activation of membrane phospholipid synthesis. Expression of XBP1(S) stimulates de novo fatty acid (FA) synthesis and the
new FAs are incorporated into diacylglycerol (DAG) and ceramide (Cer), immediate precursors of phosphatidylcholine (PtdCho), and
sphingomyelin (SM) phospholipids, respectively. The mechanism of stimulation by XBP1(S) has not yet been deﬁned. Elevation of the DAG
level alters the membrane lipid composition which leads to activation of the choline cytidylyltransferase (CCT) enzymes which produce
CDP-choline (CDP-Cho). The DAG and CDP-Cho precursors are converted to PtdCho by the choline phosphotransferase (CPT) enzymes.
Excess DAG which is not incorporated into phospholipid, is redirected and incorporated into triacylglycerol (TAG) which can accumulate in
lipid droplets. PtdCho conversion to SM is mediated by sphingomyelin synthase (SMsyn). PtdCho conversion to phosphatidylethanolamine
(PtdEtn)isroutedthroughphosphatidylserine(PtdSer).PtdEtncanalsobesynthesizedfromethanolamine(Etn)andDAGbythealternative
CDP-ethanolamine (CDP-Etn) pathway. Elevation of all three phospholipids, PtdCho, SM, and PtdEtn, contributes to membrane biogenesis
during B cell activation. Cho, choline; P-Cho, phosphocholine; CK, choline kinase; Etn, ethanolamine; P-Etn, phosphoethanolamine.
cell cycle progression, the group VIA calcium-independent
phospholipase A2 [11] and the neuropathy target esterase
[12]. Near the G1/S transition, PtdCho turnover is dimin-
ished substantially, yielding a net increase in membrane
PtdCho. Toward the latter part of the cell cycle, prior to
cytokinesis, PtdCho synthesis is downregulated [5]. This
cyclic variation in the supply of membrane phospholipid for
cell proliferation is maintained in the absence of diﬀerentia-
tion.
B cells are unique, however, and in addition to prolifera-
tion also undergo a subcellular membrane expansion as they
diﬀerentiate into antibody-secreting cells after stimulation.
There is a major increase in synthesis and secretion of
immunoglobulin (Ig) heavy (H) and light (L) chains [13].
Nascent Ig chains are cotranslationally translocated into
the endoplasmic reticulum (ER), an oxidizing, calcium-
rich environment containing many resident molecular chap-
erones and folding enzymes [14]. Within this specialized
protein folding compartment, H and L chains are assembled
into functional antibodies. Induction of high-rate Ig syn-
thesis during the diﬀerentiation process is accompanied by
expansion of the rough ER membrane, at least 3- to 4-fold
in surface area and volume [15, 16]. Thus, both proliferation
and diﬀerentiation require an increased supply of phospho-
lipids to fuel membrane and organelle biogenesis. To meet
this demand, the synthesis of phospholipids, particularly
PtdCho, increases when B cells are activated [15, 17].
3. Phosphatidylcholine Synthesis
The predominant means for PtdCho biosynthesis in mam-
malian cells proceeds via the three steps of the cytidine
diphosphocholine (CDP-choline) pathway [18]( Figure 1).
First, choline kinase (CK) phosphorylates choline in the
presence of ATP to yield phosphocholine. CKα and CKβ
are two isoforms which are soluble proteins found in the
cytosol [19, 20]. Second, choline cytidylyltransferase (CCT)
converts phosphocholine to CDP-choline in the presence
of CTP, and this is the rate-limiting step in the pathway
[21]. In every cell type examined thus far, including B
cells [17], CCT catalyzes the slow step in the pathway
and thereby determines the rate of PtdCho formation.
Comparatively small amounts of CDP-choline are found in
cells, in relation to other phospholipid precursors, as CDP-
choline is utilized almost immediately after it is made. CCT,
including all mammalian isoforms, transiently associates
with the ER membrane and the lipid composition of the
ER membrane governs CCT association and activity [22].
Elevated expression of CCT stimulates PtdCho synthesis but
often does not result in an increased amount of cellular
PtdCho in most proliferating cells due to compensatory ele-
vation of PtdCho turnover mediated by phospholipases [23,
24]. Third, the phosphocholine moiety of CDP-choline is
transferred to diacylglycerol (DAG), producing PtdCho. This
ﬁnal step can be catalyzed by either cholinephosphotrans-
ferase (CPT1) or choline/ethanolaminephosphotransferase
(CEPT1), a bifunctional enzyme that can synthesize bothBiochemistry Research International 3
choline- and ethanolamine-containing phospholipids. The
CPT enzymes are integral membrane proteins, and the CPT1
isfoundwiththeGolgiapparatuswhiletheCEPT1associates
with the ER [25, 26]. Here, we refer to the activities of
CPT1 [27] and CEPT1 [28] collectively as CPT activity. The
locations of the CPT enzymes designate the subcellular sites
of membrane biogenesis; however, enforced overexpression
of CPT activity does not enhance PtdCho synthesis [29, 30].
Rather, the supply of CDP-choline and DAG determine the
amount of PtdCho. Thus, elevated expression of the CPT
enzymes can be considered as a marker for Golgi and/or
ER membrane expansion, but not necessarily as a driver of
membrane phospholipid synthesis.
In lipopolysaccharide- (LPS-) stimulated splenic B cells,
CK activity remains fairly constant, CCT activity modestly
increases ≈2-fold, and CPT activity increases ≈6-fold [15].
These modulations of the CDP-choline pathway enzymes
in LPS-stimulated splenic B cells correlate with a 6- to 7-
fold increase in PtdCho synthesis [15, 31]. Our studies using
the CH12 B cell lymphoma indicate that increased CCT
activityispivotalforenhancedﬂuxthroughtheCDP-choline
pathway in LPS-stimulated B cells [17]. In this system,
the CCT expression and enzyme speciﬁc activity do not
increase when assayed under optimal in vitro conditions
following LPS stimulation. However, radiolabeling experi-
ments of stimulated cells demonstrate that the formation of
CDP-choline is substantially enhanced, indicating allosteric
activation of CCT by membrane lipids. Indeed, microsomal
lipids isolated from stimulated cells contain an elevated
amount of DAG and signiﬁcantly stimulate the activity of
puriﬁed recombinant CCT, compared to lipids isolated from
unstimulated cells. Thus, in this case, the formation of
DAG is key to stimulation of PtdCho synthesis: ﬁrst, by
activating CCT, and second, by providing substrate for the
CPT enzymes. The CCT, in turn, governs the fate of the
DAG as DAG is incorporated either into phospholipid under
permissive CCT conditions or into triacylglycerol (TAG)
when the CCT activity is reduced [32]( Figure 1).
4.A“Physiologic”UPR
ER stress occurs when the load of client proteins exceeds
the folding capacity of the ER, a condition that can be
catastrophic if unresolved. To rebalance load with capacity in
theER,therebyrelievingERstress,theUPRcanslowtheﬂow
of nascent polypeptides into the ER lumen and enhance the
ER machinery needed for folding and/or disposal of client
proteins [33, 34]. The mammalian UPR is orchestrated by
a trio of signaling pathways that are separately initiated by
three ubiquitously expressed ER transmembrane proteins:
PERK (PKR-like ER kinase) [35, 36], ATF6 (activating tran-
scription factor 6) α and β [37, 38], and IRE1 (ﬁrst identiﬁed
in a yeast mutant with inositol requiring phenotype) α and β
[39, 40]. The activation status and role of each UPR pathway
has been examined during the diﬀerentiation of antibody-
secreting B cells.
The PERK protein possesses a serine/threonine kinase
domain in its cytoplasmic region through which it mediates
translational attenuation [35, 36]. Upon activation, PERK
phosphorylates the α subunit of eIF-2 (eukaryotic initiation
factor-2) on serine 51, thereby impeding formation of trans-
lation initiation complexes and slowing the ﬂow of nascent
polypeptides into the ER [41, 42]. PERK does not appear to
be activated during the diﬀerentiation of antibody-secreting
B cells [43, 44] .I ns u p p o r to ft h i sc o n c e p t ,s t u d i e so fg e n e -
targetedmicerevealthatthePERKpathwayisdispensablefor
antibody secretion [43].
ATF6α and ATF6β a r et y p eI IE Rt r a n s m e m b r a n ep r o -
teins [37, 38]. Upon UPR activation, ATF6 traﬃcs from the
ER to the Golgi complex where it is clipped by the Site-1 and
Site-2 proteases [45, 46]. Once liberated from the membrane
by this process of intramembrane proteolysis, the cytosolic
N-terminal domain of ATF6 moves into the nucleus where
it functions as a transcriptional activator of genes encoding
ER resident molecular chaperones, folding enzymes and
components involved in ER-associated degradation (ERAD)
ofmisfoldedproteins[37,38,47–49].WhileATF6αandβ are
both functional, only ATF6α appears essential for induction
of ER stress responsive genes and survival of cells subjected
to ER stress conditions [48, 49]. Overexpression of active
ATF6α is suﬃcient to drive synthesis of fatty acids and
phospholipids and to induce expansion of rough ER [50],
suggesting that this UPR pathway might participate in the
diﬀerentiation of antibody-secreting B cells. Indeed, ATF6α
is activated in LPS-stimulated B cells [43, 51, 52]. However,
recent studies of ATF6α-deﬁcient mice indicate that ATF6α,
like PERK, is dispensable for the diﬀerentiation of antibody-
secreting B cells (Brewer et al., manuscript in preparation).
The IRE1 proteins contain a serine-threonine kinase
module and a C-terminal endoribonuclease domain in their
cytoplasmic regions [39, 40]. Upon activation, IRE1 executes
site-speciﬁc cleavage of Xbp1 (X-box binding protein 1)
mRNA. A 26-nt intron is excised and an undeﬁned mech-
anism then ligates the resulting 5  and 3  fragments, yielding
asplicedXbp1 mRNAwithanalteredreading frame[53–55].
Both unspliced and UPR-spliced Xbp1 transcripts encode
basic leucine zipper (bZIP) transcription factors, XBP1(U)
and XBP1(S), respectively. The XBP1(S) factor exhibits
enhanced transactivating capacity and greater stability as
compared to XBP1(U) [53–56]. Like ATF6α, XBP1(S) is
suﬃcient to upregulate synthesis of fatty acids and phos-
pholipids and to drive expansion of rough ER [30, 50].
Xbp1 is essential for optimal induction of genes encoding
proteins that function throughout the secretory pathway and
for proper development of the ER in a variety of specialized
secretory cell types [57, 58]. When B cells are stimulated
to secrete antibody, Xbp1 mRNA increases and undergoes
UPR-mediated splicing to yield XBP1(S) [3, 52, 53] ,af a c t o r
required for the generation of antibody-secreting B cells
[3, 4]. Thus, the physiologic UPR of activated B cells features
the IRE1/XBP1 pathway.
5.XBP1(S), LipidSynthesis,andERBiogenesis
Xbp1 is required for embryonic development [59]; thus, the
role of this UPR transcription factor in lymphocytes was4 Biochemistry Research International
ﬁrst investigated using the Rag-2 complementation system
[4]. Those experiments revealed that XBP1-deﬁcient B cells
are markedly defective in antibody secretion in vivo in
response to immunization and in vitro in response to LPS.
Importantly, it was shown that XBP1(S), but not XBP1(U),
eﬀectively restores the ability of XBP1-deﬁcient B cells to
secrete antibody in response to LPS in vitro [3] and is
suﬃcient to drive ER expansion [30, 58]. More recently, the
Cre-loxP system has been employed for selective deletion
of Xbp1 in B cells and studies using this system have
corroborated the earlier ﬁndings [60, 61]. Using this system,
the abundance of PtdCho was shown to increase in LPS-
stimulated XBP1-deﬁcient B cells, but to a lesser degree
than in wild-type cells [62]. The levels of PtdCho, SM, and
phosphatidylinositol were signiﬁcantly reduced in activated
XBP1-deﬁcient B cells, but PtdEtn, phosphatidylserine, and
phosphatidylglycerol were similar to corresponding amounts
in wild-type activated B cells. In addition, a meager, but
discernible, expansion of the rough ER was observed in LPS-
stimulated XBP1-deﬁcient B cells [62].
PtdCho is most drastically aﬀected by XBP1 deﬁciency
because it is the most abundant phospholipid of the ER
membranes. SM is derived directly from PtdCho, where
the phosphocholine headgroup of PtdCho is transferred
to ceramide by the SM synthase [63]( Figure 1). Thus, a
reduction in PtdCho availability would be reﬂected by a
r e d u c t i o ni nS M .T h ep a t h w a yf o rP t d C h oc o n v e r s i o nt o
PtdEtn is not as direct, however, and a second pathway
of PtdEtn synthesis via CDP-ethanolamine can bypass a
deﬁciency in PtdCho [64]. Thus, the amount of PtdEtn
is less aﬀected following activation of XBP1-deﬁcient B
cells and PtdEtn increases to almost the same extent as
in activated wild-type B cells. On the other hand, the
enforced expression of XBP1(S) in NIH-3T3 ﬁbroblasts
leads to a substantial increase in PtdEtn [30], augmenting
the XBP1(S)-independent mechanism(s) of lipogenesis. The
de novo synthesis of ceramides, key precursors in SM
production, is upregulated upon LPS stimulation [65]a n d
contributes to the increase in SM. Inhibition of ceramide
formation impairs ER expansion and protein glycosylation
in the ER lumen [65], suggesting a link among these
processes. These data establish that XBP1 is required for
maximal increases in PtdCho, SM, and rough ER in LPS-
stimulated B cells, but the mechanisms by which XBP1
mediates these events remain to be elucidated. The scheme
in Figure 1 shows a cascade of biochemical events which
illustrates how XBP1(S) stimulation of fatty acid synthesis
[50] is a key feature that drives membrane phospholipid
expansion in B cells [17]. Furthermore, these data suggest
that XBP1-independent mechanisms, as yet undeﬁned, must
also contribute to the regulation of PtdCho synthesis and ER
biogenesis during the diﬀerentiation process.
It has been proposed that the escalation of Ig synthesis
in diﬀerentiating B cells taxes the protein folding machinery
of the ER and, consequently, triggers the UPR [3]. This
model was supported by an experiment showing reduced
induction of XBP1(S) in B cells that had undergone ex vivo
Cre-mediated deletion of IgH chain prior to LPS stimulation
[3]. In contrast, recent studies have shown strong induction
of XBP1(S) in μs
−/− B cells stimulated with LPS [60, 62],
indicating that increased synthesis of soluble μ H chains
is not a prerequisite for UPR activation. In keeping with
these data, we previously showed that synthesis of XBP1(S)
precedes induction of maximal Ig translation in LPS-
stimulated CH12 B cells [52], indicating that the IRE1/XBP1
pathway is activated at an earlier stage of the diﬀerentiation
process. What then is the signal(s) for UPR activation in
stimulatedBcells?Thisremainsafundamentalquestion,and
its answer is integral to understanding the mechanisms that
drive development of antibody-secreting B cells.
6. Phosphatidylcholine Synthesis and
UPR Signaling
Mammals express three CCT isoforms that are similar in
enzymatic activity and regulation. CCTα is encoded by
the Pcyt1a gene whereas CCTβ2 and CCTβ3a r ee n c o d e d
by alternatively spliced transcripts from the Pcyt1b gene
[66]. CCTα is predominantly expressed in most tissues,
including B cells [17] ,a n di sr e q u i r e df o re a r l ye m b r y o n i c
development[67].Tissue-speciﬁcdeletionofthePcyt1agene
using the Cre-loxP system has revealed critical roles for
CCTαinspecializedsecretorycells,includingsurfactantlipid
production and secretion by alveolar epithelial cells [68],
assembly and secretion of lipoproteins by hepatocytes [69],
and cytokine secretion by activated macrophages [70]. We
recently showed that selective deletion of CCTα signiﬁcantly
hampers the ability of B cells to upregulate PtdCho synthesis
upon stimulation, and interestingly, this correlates with
heightened induction of the IRE1/XBP1 branch of the UPR
[31].
When challenged with a T cell-dependent protein anti-
gen, the animals harboring CCTα-deﬁcient B cells were
unable to produce normal levels of IgG but secreted hyper-
levels of IgM [31]. The correlation between the reduced
PtdCho synthesis and elevated IgM secretion in the CCTα-
deﬁcient B cells was counterintuitive, however, based on
the implied need for membrane PtdCho expansion dur-
ing plasma cell diﬀerentiation. Investigation of the UPR
components revealed that the impaired production of Ptd-
Cho triggers IRE-mediated splicing of Xbp1 mRNA early
after activation, thereby promoting diﬀerentiation of IgM-
secreting cells. The inability of CCTα-deﬁcient B cells to
undergo isotype switching correlates with a proliferation
defect. However, blocking proliferation by a diﬀerent mech-
anism did not elicit XBP1(S) activation, supporting the
idea that the early and potent induction of XBP1(S) by
PtdCho deﬁciency in CCTα-deﬁcient B cells accelerates and
augments the transition into antibody secretion. From these
observations, we propose that the IRE1/XBP1 branch of the
UPR responds to increased demand for phospholipids as
well as increased demand on the protein folding capacity
of the ER (Figure 2). In agreement, restriction of either
PtdCho [71] or fatty acid synthesis [72] has been shown to
elicit activation of UPR components in other systems. It is














Figure 2: XBP1(S), lipids, and secretory pathway machinery in ER biogenesis. In activated B cells, we propose that increased demand for
lipids as well as increased demand on the protein folding capacity of the ER promotes induction of the XBP1(S) transcriptional activator
via the IRE1/XBP1 branch of the UPR. The means by which these demands are sensed by the IRE1/XBP1 pathway remain unclear. XBP1(S),
via transcriptional control, upregulates expression of a large cohort of proteins involved in the synthesis, maturation, and transport of cargo
proteins within the secretory pathway. Much of this secretory machinery localizes to the ER. XBP1(S), via mechanisms that are poorly
understood, also drives lipid biosynthesis, including production of the major phospholipid PtdCho by the CDP-choline pathway. Thus,
XBP1(S) coordinates mechanisms that supply both the lipid and protein components necessary for construction of the ER.
a metabolic cue for induction of the IRE1/XBP1 pathway in
activated B cells.
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